BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/21/2021 8:24:11 AM | Browse: 829 | Download: 2107
Publication Name World Journal of Clinical Cases
Manuscript ID 64483
Country China
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Case Report
Article Title Relapsed/refractory classical Hodgkin lymphoma effectively treated by combination low-dose decitabine plus tislelizumab: A case report
Manuscript Source Unsolicited Manuscript
All Author List Xiao-Sheng Ding, Lan Mi, Yu-Qin Song, Wei-Ping Liu, Hui Yu, Ning-Jing Lin and Jun Zhu
ORCID
Author(s) ORCID Number
Xiao-Sheng Ding http://orcid.org/0000-0003-0667-6303
Lan Mi http://orcid.org/0000-0003-2618-1906
Yu-Qin Song http://orcid.org/0000-0001-5451-6481
Wei-Ping Liu http://orcid.org/0000-0002-0367-1411
Hui Yu http://orcid.org/0000-0003-1308-4832
Ning-Jing Lin http://orcid.org/0000-0002-4292-8179
Jun Zhu http://orcid.org/0000-0003-3479-2547
Funding Agency and Grant Number
Corresponding Author Jun Zhu, MD, PhD, Chief Doctor, Doctor, Doctor, Professor, Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China. zhu-jun2017@outlook.com
Key Words Immunotherapy; Hypomethylating agent; Classical Hodgkin lymphoma; Survival; Case report
Core Tip We report a 27-year-old man who complained of enlarged right-sided cervical lymph nodes and progressive pain aggravation of the right shoulder over the past 3 mo before admission. Histological analysis of lymph node biopsy was suggestive of classical Hodgkin’s lymphoma. The patient experienced failure of eight lines of therapy. Computed tomography showed that the tumors of the chest and abdomen significantly shrunk or disappeared after 3 cycles of treatment. The patient has been followed up for 11.5 mo until now, and no progressive enlargement of the tumor has been observed.
Publish Date 2021-07-21 08:24
Citation Ding XS, Mi L, Song YQ, Liu WP, Yu H, Lin NJ, Zhu J. Relapsed/refractory classical Hodgkin lymphoma effectively treated by combination low-dose decitabine plus tislelizumab: A case report. World J Clin Cases 2021; 9(21): 6041-6048
URL https://www.wjgnet.com/2307-8960/full/v9/i21/6041.htm
DOI https://dx.doi.org/10.12998/wjcc.v9.i21.6041
Full Article (PDF) WJCC-9-6041.pdf
Full Article (Word) WJCC-9-6041.docx